---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066420"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:55:08.063612+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences Q1 net income $2.6M; Zola sales up 90%; Roosevelt deal amended to 90/10 split

## Summary
- Q1 2025 net income $2.6M ($1.90/share) vs net loss of $2.4M ($1.78 loss) in Q1 2024.
- Revenue $1.2M (+22% YoY) driven by Zola coconut water sales up 90% and distribution up 70%.
- Sold patent portfolios for $750K, eliminating $1M in liabilities; operating expenses near 10-year low.
- Amended Roosevelt merger: fixed equity split 90% to Roosevelt partners, 10% to Arcadia stockholders; expected close late summer.
- Cash and cash equivalents $3.16M, down from $4.24M at Dec 31, 2024.

## SEC filing metadata
- accession: 0000950170-25-066420
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017025066420/0000950170-25-066420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017025066420/rkda-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066420
- JSON: https://secwatch.observer/filing/0000950170-25-066420.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.